Drug Profile
Human papillomavirus DNA vaccine - Merck & Co.
Alternative Names: HPV DNA vaccine - Merck & Co.Latest Information Update: 05 Oct 2006
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Cancer vaccines; DNA vaccines; Gene therapies; Papillomavirus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Human papillomavirus infections
Most Recent Events
- 05 Oct 2006 No development reported - Preclinical for Human papillomavirus infections in USA (unspecified route)
- 05 Sep 2003 Vical has reacquired the rights to apply its core vaccine technology for HPV previously licensed to Merck & Co
- 20 Aug 2002 This vaccine is still in active development